POSITIVE CORRELATION OF CRP, FOLIC ACID, AND D-DIMER WITH PROGRESSION OF CKD STAGING: A CROSS-SECTIONAL STUDY.

Afsha Mohi Ud  din; Rana  Usmani; Vivek  Ruhela; Tariq  Masood; Farah  Ahsan

doi:10.51168/sjhrafrica.v5i3.1121

Authors

Afsha Mohi Ud din PhD Scholar, Department of Biochemistry, SGRR Medical College and Hospital, Dehradun, India
Rana Usmani Associate Professor, Department of Biochemistry, SGRR Medical College and Hospital, Dehradun, India
Vivek Ruhela Associate Professor, Department of Nephrology, SGRR Medical College and Hospital, Dehradun, India
Tariq Masood Professor, Department of Biochemistry, SGRR Medical College and Hospital, Dehradun, India
Farah Ahsan Assistant Professor, Department of Biochemistry, SGRR Medical College and Hospital, Dehradun, India

DOI:

https://doi.org/10.51168/sjhrafrica.v5i3.1121

Keywords:

Chronic kidney disease, C-reactive protein, D-dimer, Folic acid

Abstract

Background

Chronic kidney disease (CKD) is characterized by kidney damage or a decline in glomerular filtration rate (GFR) over three months, often leading to various complications and stages of severity. Biomarkers such as C-reactive protein (CRP), D-dimer, and folic acid have been implicated in CKD progression, yet their correlation across different CKD stages remains to be fully elucidated. The study aims to do a comparative study of D-dimer, CRP, and Folic acid in different stages of chronic kidney disease.

Methods

The study employed a cross-sectional design. Serum samples from 150 CKD patients were collected and analyzed for CRP, D-dimer, and folic acid levels using standard laboratory procedures. Statistical analysis was performed using SPSS software and Microsoft Excel to assess the significance of biomarker variations across CKD stages.

Results

Serum CRP, D-dimer, and folic acid levels showed significant variances across CKD stages, displaying lower CRP and higher folic acid in CKD stage 1, and elevated D-dimer in later stages. Monitoring these biomarkers is pivotal for gauging CKD progression and severity, notably highlighting the rise in CRP and D-dimer with advancing CKD stages, and the higher folic acid levels seen in earlier CKD stages.

Conclusion

The study underscores the importance of monitoring biomarker levels in CKD progression, with CRP and D-dimer serving as potential indicators of disease severity. Additionally, the observed inverse relationship between folic acid levels and CKD staging warrants further investigation into its potential protective role against CKD progression.

Recommendations

Clinicians should consider incorporating regular assessment of CRP, D-dimer, and folic acid levels into CKD management protocols to better understand disease progression and tailor treatment strategies accordingly.